TerSera Therapeutics will acquire Margenza (margetuximab-cmkb) from MacroGenics
MacroGenics, Inc. and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced that they have entered into an agreement in which TerSera will acquire global rights to Margenza (margetuximab-cmkb)
Margenza was approved by the FDA in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The approval was based on results from the pivotal Phase III head-to-head clinical trial (SOPHIA) evaluating the safety and efficacy of Margenza vs. Herceptin (trastuzumab), both combined with chemotherapy.
Pursuant to the terms of the agreement, TerSera will pay MacroGenics $40 million at closing. MacroGenics may receive additional sales milestone payments of up to an aggregate of $35 million. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins